Thyroid Adenocarcinoma: Correlation between gene mutation status and selected clinical features
Maintained by TCGA GDAC Team
(Broad Institute/Dana-Farber Cancer Institute/Harvard Medical School)
Overview
Introduction
Summary
Testing the association between mutation status of 19 genes and 5 clinical features across 201 patients, 3 significant findings detected with Q value < 0.25.
-
BRAF mutation correlated to 'HISTOLOGICAL.TYPE'.
-
HRAS mutation correlated to 'HISTOLOGICAL.TYPE'.
-
NRAS mutation correlated to 'HISTOLOGICAL.TYPE'.
Results
Overview of the results
Table 1. Get Full Table Overview of the association between mutation status of 19 genes and 5 clinical features. Shown in the table are P values (Q values). Thresholded by Q value < 0.25, 3 significant findings detected.
|
Clinical Features |
AGE | GENDER |
HISTOLOGICAL TYPE |
RADIATIONS RADIATION REGIMENINDICATION |
NEOADJUVANT THERAPY |
||
| nMutated (%) | nWild-Type | t-test | Fisher's exact test | Fisher's exact test | Fisher's exact test | Fisher's exact test | |
| BRAF | 115 (57%) | 86 |
0.445 (1.00) |
0.517 (1.00) |
4.71e-18 (4.47e-16) |
0.0144 (1.00) |
0.577 (1.00) |
| HRAS | 10 (5%) | 191 |
0.732 (1.00) |
0.721 (1.00) |
0.000153 (0.0142) |
1 (1.00) |
1 (1.00) |
| NRAS | 16 (8%) | 185 |
0.818 (1.00) |
0.132 (1.00) |
9.52e-06 (0.000895) |
0.604 (1.00) |
1 (1.00) |
| POLDIP2 | 5 (2%) | 196 |
0.917 (1.00) |
0.11 (1.00) |
0.604 (1.00) |
0.267 (1.00) |
1 (1.00) |
| EMG1 | 4 (2%) | 197 |
0.686 (1.00) |
0.574 (1.00) |
1 (1.00) |
1 (1.00) |
1 (1.00) |
| EIF1AX | 3 (1%) | 198 |
0.432 (1.00) |
0.165 (1.00) |
0.0366 (1.00) |
1 (1.00) |
1 (1.00) |
| ZNF845 | 3 (1%) | 198 |
0.0965 (1.00) |
0.57 (1.00) |
0.559 (1.00) |
1 (1.00) |
1 (1.00) |
| CCDC15 | 5 (2%) | 196 |
0.139 (1.00) |
1 (1.00) |
0.121 (1.00) |
1 (1.00) |
1 (1.00) |
| TG | 9 (4%) | 192 |
0.359 (1.00) |
1 (1.00) |
0.0109 (0.999) |
1 (1.00) |
0.129 (1.00) |
| CHEK2 | 3 (1%) | 198 |
0.53 (1.00) |
1 (1.00) |
0.0985 (1.00) |
1 (1.00) |
1 (1.00) |
| PPM1D | 5 (2%) | 196 |
0.545 (1.00) |
1 (1.00) |
0.842 (1.00) |
1 (1.00) |
1 (1.00) |
| ZNF799 | 3 (1%) | 198 |
0.946 (1.00) |
1 (1.00) |
0.559 (1.00) |
1 (1.00) |
1 (1.00) |
| SLC26A11 | 3 (1%) | 198 |
0.392 (1.00) |
0.165 (1.00) |
0.723 (1.00) |
1 (1.00) |
1 (1.00) |
| KRAS | 3 (1%) | 198 |
0.888 (1.00) |
0.57 (1.00) |
0.0985 (1.00) |
1 (1.00) |
1 (1.00) |
| ARID1B | 5 (2%) | 196 |
0.52 (1.00) |
1 (1.00) |
0.219 (1.00) |
1 (1.00) |
1 (1.00) |
| COL5A3 | 4 (2%) | 197 |
0.666 (1.00) |
0.574 (1.00) |
0.289 (1.00) |
1 (1.00) |
1 (1.00) |
| DNMT3A | 4 (2%) | 197 |
0.665 (1.00) |
1 (1.00) |
0.626 (1.00) |
1 (1.00) |
1 (1.00) |
| ARFGEF2 | 4 (2%) | 197 |
0.0446 (1.00) |
1 (1.00) |
0.626 (1.00) |
1 (1.00) |
1 (1.00) |
| ZFHX3 | 4 (2%) | 197 |
0.71 (1.00) |
0.574 (1.00) |
0.289 (1.00) |
0.22 (1.00) |
0.0588 (1.00) |
Methods & Data
Copyright © 2012
Broad Institute TCGA GDAC as part of the TCGA Research Network.
All rights reserved.